A benzamide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CPI-1189

Item No. 29187

Technical Information
Formal Name
4-(acetylamino)-N-(1,1-dimethylethyl)-benzamide
CAS Number
183619-38-7
Molecular Formula
C13H18N2O2
Formula Weight
Purity
≥98%
A solid
DMF: 20mg/mLDMSO: 20mg/mLEthanol: 20mg/mLEthanol:PBS (pH 7.2) (1:5): 0.16mg/mL
λmax
265 nm
SMILES
CC(NC1=CC=C(C(NC(C)(C)C)=O)C=C1)=O
InChi Code
InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)
InChi Key
DJKNRCWSXSZACF-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    CPI-1189 is a benzamide with neuroprotective and anti-inflammatory activities.1,2,3,4,5 It inhibits phosphorylation of p38 MAPK in IL-1β-stimulated primary rat astrocytes by 70 to 80% when used at concentrations ranging from 10 to 300 nM.1 CPI-1189 (20 mg/kg per day) reduces TNF-α-induced apoptosis in the corpus callosum and septum, but not in the neocortex or basal ganglia, as well as reduces TNF-α-induced decreases in GFAP levels in isolated rat brain slices.2 It decreases the latency to find the platform in the Morris water maze, indicating reversal of memory deficits, induced by TNF-α in a rat model of AIDS dementia when administered at a dose of 20 mg/kg per day.3 CPI-1189 (30 mg/kg per day) reduces crypt loss and decreases the number of ulcers and inflammatory cells in colonic lesions in mouse models of colitis induced by TNBS or dextran sulfate sodium (DSS; Item No. 23250).4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hensley, K., Robinson, K.A., Pye, Q.N., et alCPI-1189 inhibits interleukin 1β-induced p38-mitogen-activated protein kinase phosphorylation: An explanation for its neuroprotective properties? Neurosci. Lett. 281(2-3), 179-182 (2000).

    2. Bjugstad, K.B., Flitter, W.D., Garland, W.A., et alCPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-α infusion model for AIDS dementia complex. J. Neurovirol. 6(6), 478-491 (2000).

    3. Bjugstad, K.B., Flitter, W.D., Garland, W.A., et alPreventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 795(1-2), 349-357 (1998).

    4. Greenwood-Van Meerveld, B., and Tyler, K. CPI-1189 protects against TNBS-induced colitis in a rodent model. Am. J. Pharmacol. Toxicol. 2(2), 30-38 (2007).

    5. Greenwood-Van Meerveld, B., and Tyler, K.R. CPI-1189 protects against dextran sulfate sodium-induced colitis in mice. Am. J. Pharmacol. Toxicol. 1(3), 54-59 (2006).